Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Sees Unusually-High Trading Volume After Strong Earnings

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) shares saw unusually-strong trading volume on Wednesday following a better than expected earnings announcement. Approximately 120,666 shares were traded during mid-day trading, an increase of 7% from the previous session’s volume of 112,588 shares.The stock last traded at $9.35 and had previously closed at $8.79.

The company reported $0.18 earnings per share for the quarter, topping the consensus estimate of $0.15 by $0.03. Shionogi & Co., Ltd. Unsponsored ADR had a return on equity of 13.70% and a net margin of 41.82%.The firm had revenue of $881.71 million for the quarter, compared to the consensus estimate of $895.52 million.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on SGIOY shares. Zacks Research lowered shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong sell” rating in a report on Thursday, April 16th. The Goldman Sachs Group upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR to a “hold” rating in a report on Wednesday, April 8th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Reduce”.

Shionogi & Co., Ltd. Unsponsored ADR Price Performance

The company has a market capitalization of $15.90 billion, a price-to-earnings ratio of 12.29, a price-to-earnings-growth ratio of 0.75 and a beta of 0.10. The company has a quick ratio of 5.21, a current ratio of 5.84 and a debt-to-equity ratio of 0.01. The company has a 50 day simple moving average of $10.51 and a 200 day simple moving average of $9.77.

Shionogi & Co., Ltd. Unsponsored ADR Company Profile

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.

The company’s product portfolio spans both established and innovative therapies.